GLP-1 and Peripheral Artery Disease Prevention: What the Latest Research Actually Shows

Most men don’t think about their leg arteries until something goes wrong. But peripheral artery disease — the progressive narrowing of the arteries supplying blood to the lower limbs — affects an estimated 236 million people worldwide, quietly eroding the ability to walk, exercise, and live without pain. It’s atherosclerosis from the waist down, and for the men carrying the most metabolic risk — insulin resistance, excess visceral fat, high blood pressure, chronically elevated blood sugar — it’s not a distant threat. It’s already building.

Now a growing body of clinical evidence suggests that GLP-1 receptor agonists, the class of drugs that includes semaglutide and tirzepatide, may offer meaningful protection against PAD progression and its consequences — not just through glucose control, but through mechanisms that touch inflammation, endothelial function, and cardiovascular risk at a fundamental level. The most striking data point came in 2025, when a landmark randomized trial published in The Lancet showed that semaglutide significantly increased walking capacity in men and women with symptomatic PAD. That’s not a surrogate endpoint. That’s people walking farther without stopping.

But this article isn’t just for men on GLP-1 medications. Peripheral artery disease is a lifestyle-driven condition at its core, and the strategies that prevent and slow it — aggressive metabolic control, structured exercise, anti-inflammatory nutrition, blood pressure management — apply to every man serious about protecting his long-term health. GLP-1 drugs are a powerful tool in that toolkit. They are not the whole toolkit.

What Peripheral Artery Disease Actually Does to Your Body

PAD is diagnosed when the ankle-brachial index — the ratio of blood pressure measured at the ankle versus the arm — falls below 0.90. That number reflects reduced arterial flow through the legs, caused by the same atherosclerotic plaque buildup responsible for heart attacks and strokes. Among older adults with severe PAD, more than half cannot complete a six-minute walk test without resting. That functional decline compounds rapidly: less movement means worse metabolic health, more weight gain, higher cardiovascular risk, and accelerated disease progression. It becomes a vicious cycle with no obvious exit ramp.

The classic symptom is intermittent claudication — cramping or pain in the calves or thighs during walking that resolves with rest. But by the time symptoms appear, disease is already advanced. Many men with PAD have no symptoms at all, particularly those with diabetes who have concurrent neuropathy that blunts pain signaling. This is precisely why metabolic health matters upstream: the same forces that drive insulin resistance, visceral fat accumulation, and systemic inflammation are the same forces building plaque in your femoral and popliteal arteries right now.

Current guidelines for PAD management emphasize intensive cholesterol lowering with statins, antiplatelet therapy, blood pressure control below 130/80 mmHg, SGLT2 inhibitors in diabetic patients, and — critically — supervised walking exercise. Both supervised and structured home-based walking exercise independently improve walking ability in PAD patients, which speaks to a fundamental truth: the legs respond to demand. Blood vessels adapt. Collateral circulation develops. The cardiovascular system rewards the man who keeps moving.

The Clinical Case for GLP-1 Receptor Agonists in PAD

The STRIDE trial, published in The Lancet in 2025, is the first randomized controlled trial to directly examine whether semaglutide improves functional capacity in PAD patients. The trial enrolled 792 participants — 75% male, median age 68 — all with type 2 diabetes and symptomatic PAD with intermittent claudication. They were randomized to subcutaneous semaglutide 1.0 mg once weekly or placebo for 52 weeks.

The primary endpoint was maximum walking distance on a constant-load treadmill at week 52. The semaglutide group achieved a median treatment ratio to baseline of 1.21 versus 1.08 in the placebo group — translating to an estimated treatment ratio of 1.13 (95% CI: 1.06–1.21, p=0.0004). In plain terms, the semaglutide group walked approximately 13% farther than their placebo counterparts after one year of treatment. That is a clinically meaningful functional improvement in a population that typically declines. Serious adverse events were low and comparable between groups, with gastrointestinal events being the most common treatment-related issue in the semaglutide arm.

The mechanisms behind this improvement aren’t fully established — the trial authors explicitly call for future studies to elucidate them — but the leading candidates are compelling. Semaglutide reduces systemic inflammation through pathways that extend well beyond glucose lowering. It improves endothelial function, reduces oxidative stress, lowers blood pressure, promotes significant reductions in body weight (reducing mechanical load on peripheral vasculature), and has demonstrated anti-atherosclerotic effects in animal and human studies. In men with PAD, all of these effects converge on the same endpoint: better arterial blood flow and less ischemia under exertional demand.

The STRIDE results didn’t emerge in isolation. The broader cardiovascular outcomes trial landscape for GLP-1 drugs has consistently shown benefit in high-risk atherosclerotic populations. The SOUL trial, which evaluated oral semaglutide in over 9,600 participants with type 2 diabetes and established atherosclerotic cardiovascular disease — including symptomatic PAD — was designed specifically to capture CV outcomes across this heterogeneous high-risk population. More than 70% of SOUL’s participants were male, with a mean age of 66 and over 15 years of diabetes duration. The trial’s inclusion of PAD patients alongside coronary and cerebrovascular disease patients reflects an evolving recognition that PAD deserves the same pharmacological attention as heart disease and stroke.

Meanwhile, the SURPASS-CVOT trial is evaluating tirzepatide — the dual GIP/GLP-1 receptor agonist that has produced some of the most dramatic weight loss results in clinical history — against dulaglutide in over 13,000 patients with type 2 diabetes and established atherosclerotic cardiovascular disease. With a mean BMI of 32.6 and diabetes duration of nearly 15 years at baseline, this population carries the exact metabolic burden most associated with PAD risk. The results of this trial will help clarify whether the additional GIP receptor activity of tirzepatide confers additive cardiovascular benefit compared to GLP-1 agonism alone.

For men with chronic kidney disease and diabetes — a population at significantly elevated PAD risk — a 2025 Cochrane systematic review of 42 studies and 48,148 participants found that GLP-1 receptor agonists probably reduced all-cause mortality (RR 0.85, 95% CI 0.74–0.98) and probably lowered major adverse cardiovascular events compared to placebo. The review also tracked non-fatal peripheral arterial events as a secondary outcome — a recognition that PAD sits within the broader cardiovascular risk reduction story that GLP-1 drugs are increasingly telling.

What Every Man Can Do Right Now — Medication or Not

If you’re on a GLP-1 medication, the STRIDE data should be genuinely encouraging. The functional improvements seen at 52 weeks suggest that beyond weight loss and glucose control, these drugs may be actively protecting your peripheral vasculature in ways that preserve your ability to move through life. That said, semaglutide did not replace walking exercise in the STRIDE protocol — it augmented it. The men and women in that trial were still walking on treadmills. The drug improved their capacity; exercise remained the stimulus.

If you’re not on a GLP-1 medication and have no plans to be, the prevention framework for PAD is grounded in the same metabolic fundamentals that govern all cardiovascular risk. Visceral adiposity is one of the most potent drivers of the inflammation and endothelial dysfunction that accelerate plaque formation. Reducing it — whether through caloric restriction, a well-constructed strength training program, zone 2 cardio, dietary protein prioritization, or any combination thereof — directly addresses PAD risk. The mechanism doesn’t require a prescription.

Walking itself deserves special emphasis. It may feel counterintuitive to prescribe walking as medicine for a condition that makes walking painful, but the evidence for supervised exercise in PAD is unambiguous. Structured programs that push patients to walk to near-maximal claudication pain, rest, then repeat, trigger robust adaptations in skeletal muscle metabolism, mitochondrial density, and collateral vessel development. For men without symptoms but with significant metabolic risk, regular walking and lower-body training represent genuine primary prevention — you are building the vascular reserve that PAD would have to overcome.

Nutrition strategy should prioritize the two most PAD-relevant targets: blood lipids and blood pressure. A diet built around whole protein sources, vegetables, legumes, and omega-3-rich fatty fish — while minimizing ultra-processed foods, refined carbohydrates, and excess sodium — addresses both simultaneously. Mediterranean-pattern eating has the strongest evidence base for cardiovascular risk reduction in atherosclerotic disease and is compatible with virtually every dietary philosophy, from traditional whole-food approaches to lower-carbohydrate strategies. You don’t need to pick a tribe. You need to reduce inflammatory load and support endothelial repair.

Sleep and stress management round out the picture in ways that are easy to undervalue. Chronic sleep restriction raises blood pressure, elevates cortisol, drives insulin resistance, and accelerates endothelial aging — all independently associated with PAD progression. Men who optimize their training and nutrition but chronically undersleep are leaving a significant amount of vascular protection on the table. Eight hours isn’t a luxury. It’s part of the protocol.

The Takeaway

Peripheral artery disease is not a niche condition. It affects hundreds of millions of people globally and disproportionately strikes men who carry the metabolic risk profile that dominates modern life — excess body fat, insulin resistance, hypertension, inflammation. The 2025 STRIDE trial demonstrated, for the first time in a rigorous randomized design, that semaglutide significantly improves walking capacity in PAD patients — a concrete functional outcome that matters beyond any biomarker. Ongoing trials for both semaglutide and tirzepatide are deepening our understanding of how GLP-1 receptor agonism reshapes cardiovascular risk in high-stakes populations.

But the underlying message for every man reading this is simpler than a drug trial: your arteries are not fixed. They respond to what you eat, how you move, how much you weigh, and how you manage the metabolic stressors of daily life. GLP-1 medications can accelerate the favorable changes in that equation for men who need them. For everyone else, the tools are the same ones that have always worked — progressive exercise, sound nutrition, sleep, and the commitment to treat metabolic health as the serious long-term project it actually is. Your legs will carry you as far as you’re willing to take care of them.